Overview

Rubraca is a cancer medicine for treating high-grade cancers of the ovary, fallopian tubes (the tubes connecting the ovaries to the uterus) and the peritoneum (the membrane lining the abdomen).

It is used as maintenance treatment in patients newly diagnosed with advanced cancer or in patients whose cancer has come back, and in whom the cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy. Rubraca contains the active substance rucaparib.

Rubraca can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer.

Rubraca is available as tablets to be taken twice a day. Treatment should continue until the cancer progresses or the patient has unacceptable side effects, and no longer than 2 years for patients newly diagnosed with advanced cancer. Treatment with Rubraca should be started no later than 8 weeks after the patient has finished their treatment with platinum-based chemotherapy.

For more information about using Rubraca, see the package leaflet or contact your doctor or pharmacist.

The active substance in Rubraca, rucaparib, blocks the activity of a family of proteins called poly(ADP-ribose) polymerases (PARPs) that help to repair damaged DNA in cells (both normal and cancer cells). When PARP proteins are blocked, the damaged DNA in the cancer cells cannot be repaired and the cells die as a result.

Rubraca was investigated in a main study of 564 patients with recurring ovarian cancer which had cleared (partially or completely) after treatment with platinum-based chemotherapy. Patients given Rubraca lived for 11 months without the disease coming back or getting worse compared with 5 months in patients given placebo (a dummy treatment).

Another study looked at 538 patients with newly diagnosed advanced ovarian cancer which had cleared (partially or completely) after treatment with platinum-based chemotherapy. Patients given Rubraca lived for 20 months without the disease coming back or getting worse compared with 9 months in patients given placebo.

For the full list of side effects and restrictions with Rubraca, see the package leaflet.

The most common side effects with Rubraca (which may affect more than 1 in 5 people) include tiredness or weakness, nausea (feeling sick), vomiting, anaemia (low red blood cell counts), abdominal pain (belly ache), dysgeusia (taste disturbances), increased levels of liver enzymes in the blood (which may indicate liver damage), decreased appetite, diarrhoea, neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and thrombocytopenia (low levels of platelets).

Women must not breastfeed during treatment with Rubraca and for at least 2 weeks after treatment.

Rubraca has been shown to delay worsening or return of the disease in patients whose cancer had cleared partially or completely after treatment with platinum-based chemotherapy. Regarding safety, side effects occur frequently but are generally not serious and are manageable with appropriate treatment. In addition, fewer liver and blood-related problems occur with Rubraca than with other existing treatments for these patients.

The European Medicines Agency decided that Rubraca’s benefits are greater than its risks and it can be authorised for use in the EU.

Rubraca was originally given ‘conditional authorisation’ because there was more evidence to come about the use of Rubraca outside maintenance treatment of patients. This use has since been restricted1. The authorisation has therefore been switched from a conditional to a standard marketing authorisation.


1Following a review carried out in 2022, the use of Rubraca in patients whose cancer has returned or worsened after two treatments with platinum-based chemotherapy is no longer recommended.

The company that markets Rubraca will provide final results to confirm the effectiveness of Rubraca as a maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rubraca have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rubraca are continuously monitored. Side effects reported with Rubraca are carefully evaluated and any necessary action taken to protect patients.

Rubraca received a conditional marketing authorisation valid throughout the EU on 24 May 2018. This was switched to a standard marketing authorisation on 9 November 2022.

Rubraca : EPAR - Medicine overview

български (BG) (129.4 KB - PDF)
español (ES) (103.22 KB - PDF)
čeština (CS) (126.82 KB - PDF)
dansk (DA) (104.15 KB - PDF)
Deutsch (DE) (106.77 KB - PDF)
eesti keel (ET) (100.58 KB - PDF)
ελληνικά (EL) (129.44 KB - PDF)
français (FR) (104.25 KB - PDF)
hrvatski (HR) (123.55 KB - PDF)
italiano (IT) (102.2 KB - PDF)
latviešu valoda (LV) (132.88 KB - PDF)
lietuvių kalba (LT) (125.27 KB - PDF)
magyar (HU) (125.97 KB - PDF)
Malti (MT) (127.68 KB - PDF)
Nederlands (NL) (103.76 KB - PDF)
polski (PL) (128.31 KB - PDF)
português (PT) (104.1 KB - PDF)
română (RO) (122.58 KB - PDF)
slovenčina (SK) (126.11 KB - PDF)
slovenščina (SL) (124.13 KB - PDF)
Suomi (FI) (101.05 KB - PDF)
svenska (SV) (102.46 KB - PDF)

Rubraca : EPAR - Risk management plan

Product information

Rubraca : EPAR - Product Information

български (BG) (753.63 KB - PDF)
español (ES) (646.72 KB - PDF)
čeština (CS) (650.37 KB - PDF)
dansk (DA) (633.83 KB - PDF)
Deutsch (DE) (654.94 KB - PDF)
eesti keel (ET) (652.69 KB - PDF)
ελληνικά (EL) (896.53 KB - PDF)
français (FR) (654.55 KB - PDF)
hrvatski (HR) (738.29 KB - PDF)
íslenska (IS) (660.87 KB - PDF)
italiano (IT) (668.82 KB - PDF)
latviešu valoda (LV) (679.55 KB - PDF)
lietuvių kalba (LT) (644.32 KB - PDF)
magyar (HU) (677.33 KB - PDF)
Malti (MT) (767.69 KB - PDF)
Nederlands (NL) (625.75 KB - PDF)
norsk (NO) (656.24 KB - PDF)
polski (PL) (680.77 KB - PDF)
português (PT) (640.43 KB - PDF)
română (RO) (764.73 KB - PDF)
slovenčina (SK) (661.23 KB - PDF)
slovenščina (SL) (659.18 KB - PDF)
Suomi (FI) (605.19 KB - PDF)
svenska (SV) (603.02 KB - PDF)

Latest procedure affecting product information: IB/0042/G

14/02/2024

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Rubraca : EPAR - All Authorised presentations

български (BG) (45.15 KB - PDF)
español (ES) (23.69 KB - PDF)
čeština (CS) (38.93 KB - PDF)
dansk (DA) (22.84 KB - PDF)
Deutsch (DE) (22.89 KB - PDF)
eesti keel (ET) (23.26 KB - PDF)
ελληνικά (EL) (44.8 KB - PDF)
français (FR) (22.31 KB - PDF)
hrvatski (HR) (38.98 KB - PDF)
íslenska (IS) (23.01 KB - PDF)
italiano (IT) (23.5 KB - PDF)
latviešu valoda (LV) (42.22 KB - PDF)
lietuvių kalba (LT) (41.64 KB - PDF)
magyar (HU) (30.54 KB - PDF)
Malti (MT) (38.82 KB - PDF)
Nederlands (NL) (23.48 KB - PDF)
norsk (NO) (23.07 KB - PDF)
polski (PL) (32.83 KB - PDF)
português (PT) (23.57 KB - PDF)
română (RO) (38.91 KB - PDF)
slovenčina (SK) (39.23 KB - PDF)
slovenščina (SL) (37.92 KB - PDF)
Suomi (FI) (22.75 KB - PDF)
svenska (SV) (26.67 KB - PDF)

Product details

Name of medicine
Rubraca
Active substance
Rucaparib camsylate
International non-proprietary name (INN) or common name
rucaparib
Therapeutic area (MeSH)
Ovarian Neoplasms
Anatomical therapeutic chemical (ATC) code
L01XX

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Authorisation details

EMA product number
EMEA/H/C/004272

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Marketing authorisation holder
pharmaand GmbH

Taborstrasse 1
1020 Vienna
Austria
 

Opinion adopted
06/11/2017
Marketing authorisation issued
23/05/2018
Revision
16

Assessment history

Rubraca : EPAR - Procedural steps taken and scientific information after authorisation

Rubraca-H-C-4272-II-0036 : Assessment report - Variation

CHMP post-authorisation summary of positive opinion for Rubraca (II-36)

Rubraca-H-C-4272-II-0029 : EPAR - Assessment report - Variation

Rubraca-H-A-20-1518-C-4272-0033 : Assessment report

Rubraca : EPAR - Scientific conclusions Annex IV

български (BG) (1.32 MB - PDF)
español (ES) (725.5 KB - PDF)
čeština (CS) (744.56 KB - PDF)
dansk (DA) (714.84 KB - PDF)
Deutsch (DE) (739.97 KB - PDF)
eesti keel (ET) (711.82 KB - PDF)
ελληνικά (EL) (737.75 KB - PDF)
français (FR) (723.28 KB - PDF)
hrvatski (HR) (758.94 KB - PDF)
italiano (IT) (715.12 KB - PDF)
latviešu valoda (LV) (756.77 KB - PDF)
lietuvių kalba (LT) (756.49 KB - PDF)
magyar (HU) (753.2 KB - PDF)
Malti (MT) (772.31 KB - PDF)
Nederlands (NL) (719.83 KB - PDF)
polski (PL) (756.21 KB - PDF)
português (PT) (727.02 KB - PDF)
română (RO) (755.04 KB - PDF)
slovenčina (SK) (738.97 KB - PDF)
slovenščina (SL) (754.08 KB - PDF)
Suomi (FI) (715.83 KB - PDF)
svenska (SV) (728.75 KB - PDF)

Rubraca-H-C-PSUSA-00010694-202012 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Rubraca : Orphan designation withdrawal assessment report (post-authorisation)

Rubraca-H-C-4272-II-0001 : EPAR - Assessment report - Variation

CHMP post-authorisation summary of positive opinion for Rubraca (II-01)

Rubraca : Orphan designation withdrawal assessment report (initial authorisation)

Rubraca : EPAR - Public assessment report

CHMP summary of positive opinion for Rubraca

Topics

This page was last updated on

How useful do you find this page?

Average: